
The image represents the first proof of principle for the successful regeneration of a functional organ (the skin) inside a mammal, by a technique known as AAV-based in vivo reprogramming. Epithelial (skin) tissues were generated by converting one cell type (red: mesenchymal cells) to another (green: basal keratinocytes) within a large ulcer in a laboratory mouse model.
Credit: Salk Institute
Salk scientists develop new technique to heal large ulcers by reprogramming wound cells into skin cells
Plastic surgery to treat large cutaneous ulcers, including those seen in people with severe burns, bedsores or chronic diseases such as diabetes, may someday be a thing of the past. Scientists at the Salk Institute have developed a technique to directly convert the cells in an open wound into new skin cells. The approach relies on reprogramming the cells to a stem-cell-like state and could be useful for healing skin damage, countering the effects of aging and helping us to better understand skin cancer.
“Our observations constitute an initial proof of principle for in vivo regeneration of an entire three-dimensional tissue like the skin, not just individual cell types as previously shown,” says Salk Professor Juan Carlos Izpisua Belmonte, holder of the Roger Guillemin Chair and senior author of the new paper, published in the journal Nature on September 5, 2018. “This knowledge might not only be useful for enhancing skin repair but could also serve to guide in vivo regenerative strategies in other human pathological situations, as well as during aging, in which tissue repair is impaired.”
Cutaneous ulcers—wounds that can extend through multiple layers of the skin—are typically treated surgically, by transplanting existing skin to cover the wound. However, when the ulcer is especially large, it can be difficult for surgeons to graft enough skin. In these cases, researchers are able to isolate skin stem cells from a patient, grow them in the lab and transplant them back into the patient. However, such a procedure requires an extensive amount of time, which may put the patient’s life at risk and is sometimes not effective.
Izpisua Belmonte and Salk Research Associate Masakazu Kurita, who has a background in plastic surgery, knew that a critical step in wound recovery was the migration—or transplantation—of basal keratinocytes into wounds. These stem-cell-like cells act as precursors to the different types of skin cells. But large, severe wounds that have lost multiple layers of skin no longer have any basal keratinocytes. And even as these wounds heal, the cells multiplying in the area are mainly involved in wound closure and inflammation, rather than rebuilding healthy skin.
Izpisua Belmonte and Kurita wanted to directly convert these other cells into basal keratinocytes—without ever taking them out of the body. “We set out to make skin where there was no skin to start with,” says Kurita.
The researchers first compared the levels of different proteins of the two cell types (inflammation and keratinocytes) to get a sense of what they’d need to change to reprogram the cells’ identities. They pinpointed 55 “reprogramming factors” (proteins and RNA molecules) that were potentially involved in defining the distinct identity of the basal keratinocytes. Then, through trial and error and further experiments on each potential reprogramming factor, they narrowed the list down to four factors that could mediate the conversion to basal keratinocytes.
When the team topically treated skin ulcers on mice with the four factors, the ulcers grew healthy skin (known as epithelia) within 18 days. Over time, the epithelia expanded and connected to the surrounding skin, even in large ulcers. At three and six months later, the generated cells behaved like healthy skin cells in a number of molecular, genetic and cellular tests.
The researchers are planning more studies to optimize the technique and begin testing it in additional ulcer models.
“Before going to the clinic, we have to do more studies on the long-term safety of our approach and enhance the efficiency as much as possible,” says Kurita.
Learn more: The alchemy of healing: researchers turn open wounds into skin
The Latest on: Reprogramming cells
via Google News
The Latest on: Reprogramming cells
- Researchers discover a new approach to inhibit intrahepatic cholangiocarcinomaon January 12, 2021 at 6:23 pm
Reprogramming the rich connective tissue microenvironment of a liver cancer known as intrahepatic cholangiocarcinoma (ICC) inhibits its progression and resistance to standard chemotherapy in animal ...
- Discovery of a new approach to inhibiting a highly treatment-refractory liver canceron January 12, 2021 at 9:06 am
Reprogramming the rich connective tissue microenvironment of a liver cancer known as intrahepatic cholangiocarcinoma (ICC) inhibits its progression and resistance to standard chemotherapy in animal ...
- Turn Biotechnologies Licenses Revolutionary Technology to Unwind the Effects of Aging at a Cellular Levelon January 12, 2021 at 6:10 am
Turn Biotechnologies, a company developing medicines for currently untreatable age-related conditions, announced that it has acquired the global rights for new technology that reprograms cells to undo ...
- Link between driver of ovarian cancer and metabolism opens up new therapeutic strategieson January 11, 2021 at 11:15 am
Mutations that inactivate the ARID1A gene in ovarian cancer increase utilization of the glutamine amino acid making cancer cells dependent on glutamine metabolism, according to a study by The Wistar ...
- Enlivex to Present at the H.C. Wainwright BioConnect 2021 Virtual Conferenceon January 11, 2021 at 5:00 am
Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will present at the H.C. Wainwright BioConnect 2021 Virtual ...
- Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid's Cell Therapy Programson January 11, 2021 at 4:00 am
Myeloid Therapeutics, Inc., a company harnessing and reprogramming myeloid cells to treat cancers, and MaxCyte, Inc., a global ...
- Mogrify enters research collaboration with the MRC Laboratory of Molecular Biologyon January 11, 2021 at 2:24 am
Mogrify Limited and the MRC Laboratory of Molecular Biology (LMB), today announced an exploratory research collaboration.
- India Stem Cell Market to Surpass USD 1.27 Billion until FY2026 – TechSci Researchon January 8, 2021 at 12:30 am
Growing industry attention on stem cell research and surging demand for regenerative medicines to drive India stem cell market According to TechSci Research report India Stem Cell Market By Product ...
- ImmCelz® Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patientson January 6, 2021 at 4:45 am
PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTC: CELZ) commented today on a peer-reviewed publication from the University of ...
- Tech Can Solve Stem Cell Sector’s Manufacturing Challengeson January 5, 2021 at 1:04 pm
But stem cells have wider therapeutic potential. In theory they can be reprogrammed to regenerate tissues damaged in diseases ranging including type 1 diabetes, Parkinson’s, amyotrophic lateral ...
via Bing News